<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240306193047&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240306193047&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 07 Mar 2024 00:30:48 +0000</lastbuilddate>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Extracellular vesicles as vehicles for drug delivery to the heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38447179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae099. doi: 10.1093/eurheartj/ehae099. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38447179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38447179</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae099>10.1093/eurheartj/ehae099</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38447179</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Nazma F Ilahibaks</dc:creator>
<dc:creator>Zhiyong Lei</dc:creator>
<dc:creator>Joost P G Sluijter</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Extracellular vesicles as vehicles for drug delivery to the heart</dc:title>
<dc:identifier>pmid:38447179</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae099</dc:identifier>
</item>
<item>
<title>A healthy diet should consider environmental impact</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38447170/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae134. doi: 10.1093/eurheartj/ehae134. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38447170/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38447170</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae134>10.1093/eurheartj/ehae134</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38447170</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Walter C Willett</dc:creator>
<dc:creator>Frank B Hu</dc:creator>
<dc:creator>Nita G Forouhi</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A healthy diet should consider environmental impact</dc:title>
<dc:identifier>pmid:38447170</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae134</dc:identifier>
</item>
<item>
<title>Unsuccessful ageing: from frailty to cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38447158/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae098. doi: 10.1093/eurheartj/ehae098. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38447158/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38447158</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae098>10.1093/eurheartj/ehae098</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38447158</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Jonathan Afilalo</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Unsuccessful ageing: from frailty to cardiovascular disease</dc:title>
<dc:identifier>pmid:38447158</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae098</dc:identifier>
</item>
<item>
<title>Open Access Note Added to Article Information</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38446487/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 6. doi: 10.1001/jamacardio.2024.0216. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38446487/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38446487</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0216>10.1001/jamacardio.2024.0216</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38446487</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:date>2024-03-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Open Access Note Added to Article Information</dc:title>
<dc:identifier>pmid:38446487</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0216</dc:identifier>
</item>
<item>
<title>Great debate: symptomatic moderate aortic stenosis should undergo intervention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38446449/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae050. doi: 10.1093/eurheartj/ehae050. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38446449/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38446449</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae050>10.1093/eurheartj/ehae050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38446449</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Jeroen J Bax</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Nina Ajmone Marsan</dc:creator>
<dc:creator>Helmut Baumgartner</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Great debate: symptomatic moderate aortic stenosis should undergo intervention</dc:title>
<dc:identifier>pmid:38446449</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae050</dc:identifier>
</item>
<item>
<title>Deep Learning-Augmented ECG Analysis for Screening and Genotype Prediction of Congenital Long QT Syndrome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38446445/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: The deep learning model improved detection of congenital LQTS from resting ECGs and allowed for differentiation between the 2 most common genetic subtypes. Broader validation over an unselected general population may support application of this model to patients with suspected LQTS.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 6. doi: 10.1001/jamacardio.2024.0039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Congenital long QT syndrome (LQTS) is associated with syncope, ventricular arrhythmias, and sudden death. Half of patients with LQTS have a normal or borderline-normal QT interval despite LQTS often being detected by QT prolongation on resting electrocardiography (ECG).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To develop a deep learning-based neural network for identification of LQTS and differentiation of genotypes (LQTS1 and LQTS2) using 12-lead ECG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This diagnostic accuracy study used ECGs from patients with suspected inherited arrhythmia enrolled in the Hearts in Rhythm Organization Registry (HiRO) from August 2012 to December 2021. The internal dataset was derived at 2 sites and an external validation dataset at 4 sites within the HiRO Registry; an additional cross-sectional validation dataset was from the Montreal Heart Institute. The cohort with LQTS included probands and relatives with pathogenic or likely pathogenic variants in KCNQ1 or KCNH2 genes with normal or prolonged corrected QT (QTc) intervals.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: Convolutional neural network (CNN) discrimination between LQTS1, LQTS2, and negative genetic test results.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The main outcomes were area under the curve (AUC), F1 scores, and sensitivity for detecting LQTS and differentiating genotypes using a CNN method compared with QTc-based detection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 4521 ECGs from 990 patients (mean [SD] age, 42 [18] years; 589 [59.5%] female) were analyzed. External validation within the national registry (101 patients) demonstrated the CNN's high diagnostic capacity for LQTS detection (AUC, 0.93; 95% CI, 0.89-0.96) and genotype differentiation (AUC, 0.91; 95% CI, 0.86-0.96). This surpassed expert-measured QTc intervals in detecting LQTS (F1 score, 0.84 [95% CI, 0.78-0.90] vs 0.22 [95% CI, 0.13-0.31]; sensitivity, 0.90 [95% CI, 0.86-0.94] vs 0.36 [95% CI, 0.23-0.47]), including in patients with normal or borderline QTc intervals (F1 score, 0.70 [95% CI, 0.40-1.00]; sensitivity, 0.78 [95% CI, 0.53-0.95]). In further validation in a cross-sectional cohort (406 patients) of high-risk patients and genotype-negative controls, the CNN detected LQTS with an AUC of 0.81 (95% CI, 0.80-0.85), which was better than QTc interval-based detection (AUC, 0.74; 95% CI, 0.69-0.78).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The deep learning model improved detection of congenital LQTS from resting ECGs and allowed for differentiation between the 2 most common genetic subtypes. Broader validation over an unselected general population may support application of this model to patients with suspected LQTS.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38446445/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38446445</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0039>10.1001/jamacardio.2024.0039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38446445</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>River Jiang</dc:creator>
<dc:creator>Christopher C Cheung</dc:creator>
<dc:creator>Marta Garcia-Montero</dc:creator>
<dc:creator>Brianna Davies</dc:creator>
<dc:creator>Jason Cao</dc:creator>
<dc:creator>Damian Redfearn</dc:creator>
<dc:creator>Zachary M Laksman</dc:creator>
<dc:creator>Steffany Grondin</dc:creator>
<dc:creator>Joseph Atallah</dc:creator>
<dc:creator>Carolina A Escudero</dc:creator>
<dc:creator>Julia Cadrin-Tourigny</dc:creator>
<dc:creator>Shubhayan Sanatani</dc:creator>
<dc:creator>Christian Steinberg</dc:creator>
<dc:creator>Jacqueline Joza</dc:creator>
<dc:creator>Robert Avram</dc:creator>
<dc:creator>Rafik Tadros</dc:creator>
<dc:creator>Andrew D Krahn</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Deep Learning-Augmented ECG Analysis for Screening and Genotype Prediction of Congenital Long QT Syndrome</dc:title>
<dc:identifier>pmid:38446445</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0039</dc:identifier>
</item>
<item>
<title>Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38446436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this study, ATTR amyloidosis was characterized by distinct patterns of functional impairment between all disease phenotypes. A high prevalence of chronotropic incompetence, EOV, and ventilatory inefficiency were characteristic of this population. CPET parameters were associated with amyloid burden by CMR and with peak VO2, and SBP, which have been shown to be independent predictors of mortality. These findings suggest that CPET may be useful in characterizing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Mar 6. doi: 10.1001/jamacardio.2024.0022. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Cardiopulmonary exercise testing (CPET) has an established role in the assessment of patients with heart failure. However, data are lacking in patients with transthyretin (ATTR) amyloidosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To use CPET to characterize the spectrum of functional phenotypes in patients with ATTR amyloidosis and assess their association with the cardiac amyloid burden as well as the association between CPET parameters and prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING AND PARTICIPANTS: This single-center study evaluated patients diagnosed with ATTR amyloidosis from May 2019 to September 2022 who underwent CPET at the National Amyloidosis Centre. Of 1045 patients approached, 506 were included and completed the study. Patients were excluded if they had an absolute contraindication to CPET or declined participation. The mean (SD) follow-up period was 22.4 (11.6) months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Comparison of CPET parameters across disease phenotypes (ATTR with cardiomyopathy [ATTR-CM], polyneuropathy, or both [ATTR-mixed]), differences in CPET parameters based on degree of amyloid infiltration (as measured by cardiovascular magnetic resonance [CMR] with extracellular volume mapping), and association between CPET parameters and prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the 506 patients with ATTR amyloidosis included in this study, the mean (SD) age was 73.5 (10.2) years, and 457 participants (90.3%) were male. Impairment in functional capacity was highly prevalent. Functional impairment in ATTR-CM and ATTR-mixed phenotypes (peak mean [SD] oxygen consumption [VO2], 14.5 [4.3] mL/kg/min and 15.7 [6.2] mL/kg/min, respectively) was observed alongside impairment in the oxygen pulse, with ventilatory efficiency highest in ATTR-CM (mean [SD] ventilatory efficiency/volume of carbon dioxide expired slope, 38.1 [8.6]). Chronotropic incompetence and exercise oscillatory ventilation (EOV) were highly prevalent across all phenotypes, with both the prevalence and severity being higher than in heart failure from different etiologies. Worsening of amyloid burden on CMR was associated with decline in multiple CPET parameters, although chronotropic response and EOV remained abnormal irrespective of amyloid burden. On multivariable Cox regression analysis, peak VO2 and peak systolic blood pressure (SBP) were independently associated with prognosis (peak VO2: hazard ratio, 0.89 [95% CI, 0.81-0.99; P = .03]; peak SBP: hazard ratio, 0.98 [95% CI, 0.97-0.99; P &lt; .001]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this study, ATTR amyloidosis was characterized by distinct patterns of functional impairment between all disease phenotypes. A high prevalence of chronotropic incompetence, EOV, and ventilatory inefficiency were characteristic of this population. CPET parameters were associated with amyloid burden by CMR and with peak VO2, and SBP, which have been shown to be independent predictors of mortality. These findings suggest that CPET may be useful in characterizing distinct patterns of functional impairment across the spectrum of amyloid infiltration and predicting outcomes, and potentially offers a more comprehensive method of evaluating functional capacity for future prospective studies.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38446436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38446436</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0022>10.1001/jamacardio.2024.0022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38446436</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Rishi K Patel</dc:creator>
<dc:creator>Francesco Bandera</dc:creator>
<dc:creator>Lucia Venneri</dc:creator>
<dc:creator>Aldostefano Porcari</dc:creator>
<dc:creator>Yousuf Razvi</dc:creator>
<dc:creator>Adam Ioannou</dc:creator>
<dc:creator>Liza Chacko</dc:creator>
<dc:creator>Ana Martinez-Naharro</dc:creator>
<dc:creator>Muhammad U Rauf</dc:creator>
<dc:creator>Daniel Knight</dc:creator>
<dc:creator>James Brown</dc:creator>
<dc:creator>Aviva Petrie</dc:creator>
<dc:creator>Ashutosh Wechalekar</dc:creator>
<dc:creator>Carol Whelan</dc:creator>
<dc:creator>Helen Lachmann</dc:creator>
<dc:creator>Vivek Muthurangu</dc:creator>
<dc:creator>Marco Guazzi</dc:creator>
<dc:creator>Philip N Hawkins</dc:creator>
<dc:creator>Julian D Gillmore</dc:creator>
<dc:creator>Marianna Fontana</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis</dc:title>
<dc:identifier>pmid:38446436</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0022</dc:identifier>
</item>
<item>
<title>Future cardiovascular healthcare via magnetic resonance imaging-driven robotics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38446426/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae095. doi: 10.1093/eurheartj/ehae095. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38446426/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38446426</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae095>10.1093/eurheartj/ehae095</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38446426</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Peter Lloyd</dc:creator>
<dc:creator>Erica Dall'Armellina</dc:creator>
<dc:creator>Jurgen E Schneider</dc:creator>
<dc:creator>Pietro Valdastri</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Future cardiovascular healthcare via magnetic resonance imaging-driven robotics</dc:title>
<dc:identifier>pmid:38446426</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae095</dc:identifier>
</item>
<item>
<title>Stable incidence and outcomes for patients with incident aortic stenosis: how can we translate excellent trial data into improved clinical outcomes in the population?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38446140/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae078. doi: 10.1093/eurheartj/ehae078. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38446140/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38446140</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae078>10.1093/eurheartj/ehae078</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38446140</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Andreas Martinsson</dc:creator>
<dc:creator>Ravi Rasalingam</dc:creator>
<dc:creator>Anders Jeppsson</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Stable incidence and outcomes for patients with incident aortic stenosis: how can we translate excellent trial data into improved clinical outcomes in the population?</dc:title>
<dc:identifier>pmid:38446140</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae078</dc:identifier>
</item>
<item>
<title>Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38446126/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: This hypothesis-generating analysis suggests that anaemia or TSAT &lt; 20% with ferritin >; 100 µg/L might identify patients with heart failure who obtain greater benefit from intravenous iron. This interpretation requires confirmation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae086. doi: 10.1093/eurheartj/ehae086. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: What is the relationship between blood tests for iron deficiency, including anaemia, and the response to intravenous iron in patients with heart failure?</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the IRONMAN trial, 1137 patients with heart failure, ejection fraction ≤ 45%, and either serum ferritin &lt; 100 µg/L or transferrin saturation (TSAT) &lt; 20% were randomized to intravenous ferric derisomaltose (FDI) or usual care. Relationships were investigated between baseline anaemia severity, ferritin and TSAT, to changes in haemoglobin from baseline to 4 months, Minnesota Living with Heart Failure (MLwHF) score and 6-minute walk distance achieved at 4 months, and clinical events, including heart failure hospitalization (recurrent) or cardiovascular death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The rise in haemoglobin after administering FDI, adjusted for usual care, was greater for lower baseline TSAT (Pinteraction &lt; .0001) and ferritin (Pinteraction = .028) and more severe anaemia (Pinteraction = .014). MLwHF scores at 4 months were somewhat lower (better) with FDI for more anaemic patients (overall Pinteraction = .14; physical Pinteraction = .085; emotional Pinteraction = .043) but were not related to baseline TSAT or ferritin. Blood tests did not predict difference in achieved walking distance for those randomized to FDI compared to control. The absence of anaemia or a TSAT ≥ 20% was associated with lower event rates and little evidence of benefit from FDI. More severe anaemia or TSAT &lt; 20%, especially when ferritin was ≥100 µg/L, was associated with higher event rates and greater absolute reductions in events with FDI, albeit not statistically significant.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: This hypothesis-generating analysis suggests that anaemia or TSAT &lt; 20% with ferritin >; 100 µg/L might identify patients with heart failure who obtain greater benefit from intravenous iron. This interpretation requires confirmation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38446126/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38446126</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae086>10.1093/eurheartj/ehae086</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38446126</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>John G F Cleland</dc:creator>
<dc:creator>Philip A Kalra</dc:creator>
<dc:creator>Pierpaolo Pellicori</dc:creator>
<dc:creator>Fraser J Graham</dc:creator>
<dc:creator>Paul W X Foley</dc:creator>
<dc:creator>Iain B Squire</dc:creator>
<dc:creator>Peter J Cowburn</dc:creator>
<dc:creator>Alison Seed</dc:creator>
<dc:creator>Andrew L Clark</dc:creator>
<dc:creator>Ben Szwejkowski</dc:creator>
<dc:creator>Prithwish Banerjee</dc:creator>
<dc:creator>Justin Cooke</dc:creator>
<dc:creator>Mark Francis</dc:creator>
<dc:creator>Piers Clifford</dc:creator>
<dc:creator>Aaron Wong</dc:creator>
<dc:creator>Colin Petrie</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Elizabeth A Thomson</dc:creator>
<dc:creator>Kirsty Wetherall</dc:creator>
<dc:creator>Michele Robertson</dc:creator>
<dc:creator>Ian Ford</dc:creator>
<dc:creator>Paul R Kalra</dc:creator>
<dc:creator>IRONMAN Study Group</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Intravenous iron for heart failure, iron deficiency definitions, and clinical response: the IRONMAN trial</dc:title>
<dc:identifier>pmid:38446126</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae086</dc:identifier>
</item>
<item>
<title>Novel cardioprotective approaches in ischaemic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38445879/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae058. doi: 10.1093/eurheartj/ehae058. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38445879/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38445879</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae058>10.1093/eurheartj/ehae058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38445879</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Gemma Vilahur</dc:creator>
<dc:creator>Monika Radike</dc:creator>
<dc:creator>Lina Badimon</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Novel cardioprotective approaches in ischaemic heart disease</dc:title>
<dc:identifier>pmid:38445879</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae058</dc:identifier>
</item>
<item>
<title>Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38445853/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehad890. doi: 10.1093/eurheartj/ehad890. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38445853/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38445853</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad890>10.1093/eurheartj/ehad890</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38445853</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Marie-A Chaix</dc:creator>
<dc:creator>Annie Dore</dc:creator>
<dc:creator>Blandine Mondésert</dc:creator>
<dc:creator>François-Pierre Mongeon</dc:creator>
<dc:creator>Véronique Roy</dc:creator>
<dc:creator>Charles Desrosiers-Gagnon</dc:creator>
<dc:creator>Marie-Claude Guertin</dc:creator>
<dc:creator>Michel White</dc:creator>
<dc:creator>Réda Ibrahim</dc:creator>
<dc:creator>Eileen O'Meara</dc:creator>
<dc:creator>Jean-Lucien Rouleau</dc:creator>
<dc:creator>Paul Khairy</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial</dc:title>
<dc:identifier>pmid:38445853</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad890</dc:identifier>
</item>
<item>
<title>Implantable loop recorders in patients with Brugada syndrome: the BruLoop study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38445836/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: ILR detects arrhythmic events in nearly 30% of symptomatic BrS patients, leading to appropriate therapy in 70% of them. The most commonly detected arrhythmias are AAs and BAs, while VAs are detected only in 7% of cases. Symptom status can be used to guide ILR implantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae133. doi: 10.1093/eurheartj/ehae133. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Available data on continuous rhythm monitoring by implantable loop recorders (ILRs) in patients with Brugada syndrome (BrS) are scarce. The aim of this multi-centre study was to evaluate the diagnostic yield and clinical implication of a continuous rhythm monitoring strategy by ILRs in a large cohort of BrS patients and to assess the precise arrhythmic cause of syncopal episodes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A total of 370 patients with BrS and ILRs (mean age 43.5 ± 15.9, 33.8% female, 74.1% symptomatic) from 18 international centers were included. Patients were followed with continuous rhythm monitoring for a median follow-up of 3 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During follow-up, an arrhythmic event was recorded in 30.7% of symptomatic patients [18.6% atrial arrhythmias (AAs), 10.2% bradyarrhythmias (BAs), and 7.3% ventricular arrhythmias (VAs)]. In patients with recurrent syncope, the aetiology was arrhythmic in 22.4% (59.3% BAs, 25.0% VAs, and 15.6% AAs). The ILR led to drug therapy initiation in 11.4%, ablation procedure in 10.9%, implantation of a pacemaker in 2.5%, and a cardioverter-defibrillator in 8%. At multivariate analysis, the presence of symptoms [hazard ratio (HR) 2.5, P = .001] and age >;50 years (HR 1.7, P = .016) were independent predictors of arrhythmic events, while inducibility of ventricular fibrillation at the electrophysiological study (HR 9.0, P &lt; .001) was a predictor of VAs.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: ILR detects arrhythmic events in nearly 30% of symptomatic BrS patients, leading to appropriate therapy in 70% of them. The most commonly detected arrhythmias are AAs and BAs, while VAs are detected only in 7% of cases. Symptom status can be used to guide ILR implantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38445836/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38445836</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae133>10.1093/eurheartj/ehae133</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38445836</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Marco Bergonti</dc:creator>
<dc:creator>Frederic Sacher</dc:creator>
<dc:creator>Elena Arbelo</dc:creator>
<dc:creator>Lia Crotti</dc:creator>
<dc:creator>Avi Sabbag</dc:creator>
<dc:creator>Michela Casella</dc:creator>
<dc:creator>Johan Saenen</dc:creator>
<dc:creator>Andrea Rossi</dc:creator>
<dc:creator>Cinzia Monaco</dc:creator>
<dc:creator>Luigi Pannone</dc:creator>
<dc:creator>Paolo Compagnucci</dc:creator>
<dc:creator>Vincenzo Russo</dc:creator>
<dc:creator>Eyal Heller</dc:creator>
<dc:creator>Amato Santoro</dc:creator>
<dc:creator>Paola Berne</dc:creator>
<dc:creator>Antonio Bisignani</dc:creator>
<dc:creator>Enrico Baldi</dc:creator>
<dc:creator>Olivier Van Leuven</dc:creator>
<dc:creator>Federico Migliore</dc:creator>
<dc:creator>Lorenzo Marcon</dc:creator>
<dc:creator>Federica Dagradi</dc:creator>
<dc:creator>Irene Sfondrini</dc:creator>
<dc:creator>Federico Landra</dc:creator>
<dc:creator>Angelo Comune</dc:creator>
<dc:creator>María Cespón-Fernández</dc:creator>
<dc:creator>Martina Nesti</dc:creator>
<dc:creator>Francesco Santoro</dc:creator>
<dc:creator>Michele Magnocavallo</dc:creator>
<dc:creator>Alessandro Vicentini</dc:creator>
<dc:creator>Sergio Conti</dc:creator>
<dc:creator>Valentina Ribatti</dc:creator>
<dc:creator>Pedro Brugada</dc:creator>
<dc:creator>Carlo de Asmundis</dc:creator>
<dc:creator>Josep Brugada</dc:creator>
<dc:creator>Claudio Tondo</dc:creator>
<dc:creator>Peter J Schwartz</dc:creator>
<dc:creator>Michel Haissaguerre</dc:creator>
<dc:creator>Angelo Auricchio</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Implantable loop recorders in patients with Brugada syndrome: the BruLoop study</dc:title>
<dc:identifier>pmid:38445836</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae133</dc:identifier>
</item>
<item>
<title>Urinary thromboxane and risk of cardiovascular events: role of aspirin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38445763/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 6:ehae003. doi: 10.1093/eurheartj/ehae003. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38445763/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38445763</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae003>10.1093/eurheartj/ehae003</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38445763</guid>
<pubDate>Wed, 06 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>John W Eikelboom</dc:creator>
<dc:creator>Paul C Kruger</dc:creator>
<dc:date>2024-03-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Urinary thromboxane and risk of cardiovascular events: role of aspirin</dc:title>
<dc:identifier>pmid:38445763</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae003</dc:identifier>
</item>
<item>
<title>A mouse DRG genetic toolkit reveals morphological and physiological diversity of somatosensory neuron subtypes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442711/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>Dorsal root ganglia (DRG) somatosensory neurons detect mechanical, thermal, and chemical stimuli acting on the body. Achieving a holistic view of how different DRG neuron subtypes relay neural signals from the periphery to the CNS has been challenging with existing tools. Here, we develop and curate a mouse genetic toolkit that allows for interrogating the properties and functions of distinct cutaneous targeting DRG neuron subtypes. These tools have enabled a broad morphological analysis, which...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Feb 28:S0092-8674(24)00127-2. doi: 10.1016/j.cell.2024.02.006. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Dorsal root ganglia (DRG) somatosensory neurons detect mechanical, thermal, and chemical stimuli acting on the body. Achieving a holistic view of how different DRG neuron subtypes relay neural signals from the periphery to the CNS has been challenging with existing tools. Here, we develop and curate a mouse genetic toolkit that allows for interrogating the properties and functions of distinct cutaneous targeting DRG neuron subtypes. These tools have enabled a broad morphological analysis, which revealed distinct cutaneous axon arborization areas and branching patterns of the transcriptionally distinct DRG neuron subtypes. Moreover, in vivo physiological analysis revealed that each subtype has a distinct threshold and range of responses to mechanical and/or thermal stimuli. These findings support a model in which morphologically and physiologically distinct cutaneous DRG sensory neuron subtypes tile mechanical and thermal stimulus space to collectively encode a wide range of natural stimuli.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442711/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38442711</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.006>10.1016/j.cell.2024.02.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442711</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Lijun Qi</dc:creator>
<dc:creator>Michael Iskols</dc:creator>
<dc:creator>David Shi</dc:creator>
<dc:creator>Pranav Reddy</dc:creator>
<dc:creator>Christopher Walker</dc:creator>
<dc:creator>Karina Lezgiyeva</dc:creator>
<dc:creator>Tiphaine Voisin</dc:creator>
<dc:creator>Mathias Pawlak</dc:creator>
<dc:creator>Vijay K Kuchroo</dc:creator>
<dc:creator>Isaac M Chiu</dc:creator>
<dc:creator>David D Ginty</dc:creator>
<dc:creator>Nikhil Sharma</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A mouse DRG genetic toolkit reveals morphological and physiological diversity of somatosensory neuron subtypes</dc:title>
<dc:identifier>pmid:38442711</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.006</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae112. doi: 10.1093/eurheartj/ehae112. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38442294</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae112>10.1093/eurheartj/ehae112</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442294</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Francesco Cosentino</dc:creator>
<dc:creator>Christopher Paul Cannon</dc:creator>
<dc:creator>Nikolaus Marx</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in diabetes and metabolic disorders</dc:title>
<dc:identifier>pmid:38442294</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae112</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in interventional cardiology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae110. doi: 10.1093/eurheartj/ehae110. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38442292</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae110>10.1093/eurheartj/ehae110</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442292</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Emanuele Barbato</dc:creator>
<dc:creator>Margaret McEntegart</dc:creator>
<dc:creator>Tommaso Gori</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in interventional cardiology</dc:title>
<dc:identifier>pmid:38442292</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae110</dc:identifier>
</item>
<item>
<title>Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442291/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae102. doi: 10.1093/eurheartj/ehae102. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442291/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38442291</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae102>10.1093/eurheartj/ehae102</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442291</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Naisam Abbas</dc:creator>
<dc:creator>Jonas A Haas</dc:creator>
<dc:creator>Ke Xiao</dc:creator>
<dc:creator>Maximilian Fuchs</dc:creator>
<dc:creator>Annette Just</dc:creator>
<dc:creator>Andreas Pich</dc:creator>
<dc:creator>Filippo Perbellini</dc:creator>
<dc:creator>Christopher Werlein</dc:creator>
<dc:creator>Fabio Ius</dc:creator>
<dc:creator>Arjang Ruhparwar</dc:creator>
<dc:creator>Jan Fiedler</dc:creator>
<dc:creator>Natalie Weber</dc:creator>
<dc:creator>Thomas Thum</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Inhibition of miR-21: cardioprotective effects in human failing myocardium ex vivo</dc:title>
<dc:identifier>pmid:38442291</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae102</dc:identifier>
</item>
<item>
<title>The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442290/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae113. doi: 10.1093/eurheartj/ehae113. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442290/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38442290</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae113>10.1093/eurheartj/ehae113</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442290</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Juan Carlos Kaski</dc:creator>
<dc:creator>Rasha Al-Lamee</dc:creator>
<dc:creator>William E Boden</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The year in cardiovascular medicine 2023: the top 10 papers in ischaemic heart disease</dc:title>
<dc:identifier>pmid:38442290</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae113</dc:identifier>
</item>
<item>
<title>Cardiac magnetic resonance in the assessment of the anomalous right coronary artery originating from the left sinus of Valsalva</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442289/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae129. doi: 10.1093/eurheartj/ehae129. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442289/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38442289</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae129>10.1093/eurheartj/ehae129</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442289</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Alberto Cipriani</dc:creator>
<dc:creator>Mauro Lo Rito</dc:creator>
<dc:creator>Silvia Pica</dc:creator>
<dc:creator>Monica De Gaspari</dc:creator>
<dc:creator>Ilaria Rigato</dc:creator>
<dc:creator>Martina Perazzolo Marra</dc:creator>
<dc:creator>Giorgio De Conti</dc:creator>
<dc:creator>Simone Corradin</dc:creator>
<dc:creator>Raffaella Motta</dc:creator>
<dc:creator>Valeria Pergola</dc:creator>
<dc:creator>Francesco Secchi</dc:creator>
<dc:creator>Massimo Lombardi</dc:creator>
<dc:creator>Barbara Bauce</dc:creator>
<dc:creator>Alessandro Zorzi</dc:creator>
<dc:creator>Gaetano Thiene</dc:creator>
<dc:creator>Cristina Basso</dc:creator>
<dc:creator>Silvana Molossi</dc:creator>
<dc:creator>Massimo Antonio Padalino</dc:creator>
<dc:creator>Domenico Corrado</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cardiac magnetic resonance in the assessment of the anomalous right coronary artery originating from the left sinus of Valsalva</dc:title>
<dc:identifier>pmid:38442289</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae129</dc:identifier>
</item>
<item>
<title>Frailty, genetic predisposition, and incident atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38442287/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240306193047&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Mar 5:ehae130. doi: 10.1093/eurheartj/ehae130. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38442287/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240306193047&v=2.18.0.post9+e462414">38442287</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae130>10.1093/eurheartj/ehae130</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38442287</guid>
<pubDate>Tue, 05 Mar 2024 06:00:00 -0500</pubDate>
<dc:creator>Ying Sun</dc:creator>
<dc:creator>Yinuo Zhou</dc:creator>
<dc:creator>Bowei Yu</dc:creator>
<dc:creator>Kun Zhang</dc:creator>
<dc:creator>Bin Wang</dc:creator>
<dc:creator>Xiao Tan</dc:creator>
<dc:creator>Yingli Lu</dc:creator>
<dc:creator>Ningjian Wang</dc:creator>
<dc:date>2024-03-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Frailty, genetic predisposition, and incident atrial fibrillation</dc:title>
<dc:identifier>pmid:38442287</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae130</dc:identifier>
</item>





























</channel>
</rss>